Blogs

Demand for nucleic acid therapeutics (NATs) is increasing as mRNA-based products, oligonucleotide therapeutics and gene editing applications expand from niche rare diseases into mainstream, high-prevalence indications. An example of this is Zilebesiran, a novel RNA interference (RNAi) therapeutic that is currently advancing through late-stage clinical trials for the treatment of hypertension [1]. This illustrates a […]

Developing new RNA therapeutics requires years of dedicated effort. However, taking a program from the promise of preclinical models into the reality of clinical development presents the fundamental challenge of scale. Innovators must find a way to manufacture their drug, scaling up from grams to kilograms or even tons, all while maintaining quality, consistency and […]

The rise of nucleic acid therapeutics (NATs) — including oligonucleotides such as siRNA, mRNA-based products, and CRISPR-based drugs — is transforming modern medicine. These precise and potent modalities are advancing rapidly through development, posing new challenges for achieving scalable and compliant manufacturing.   Early-stage NAT developers often rely on multiple specialized vendors across different production […]

This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.